{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:14:15Z","timestamp":1780938855733,"version":"3.54.1"},"reference-count":9,"publisher":"Baishideng Publishing Group Inc.","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Gastroenterol"],"abstract":"<jats:p>Hepatitis B virus (HBV) reactivation (HBVr) represents a severe and potentially life-threatening condition, and preventive measures are available through blood test screening or prophylactic therapy administration. The assessment of HBVr traditionally considers factors such as HBV profile, including hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen, along with type of medication (chemotherapy; immunomodulants). Nevertheless, consideration of possible patient\u2019s underlying tumor and the specific malignancy type (solid or hematologic) plays a crucial role and needs to be assessed for decision-making process.<\/jats:p>","DOI":"10.3748\/wjg.v30.i9.1253","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T09:23:36Z","timestamp":1709630616000},"page":"1253-1256","source":"Crossref","is-referenced-by-count":9,"title":["Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis"],"prefix":"10.3748","volume":"30","author":[{"given":"Francesca","family":"Colapietro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Voza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i33.4942"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.003"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280325"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.04.006"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010231"},{"key":"B6","unstructured":"AstraZeneca.   Calquence tablet formulation approved in the US across current indications. 2022. [cited 25 September 2023]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/calquence-tablet-formulation-approved-in-the-us-across-current-indications.html"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-826495"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13575"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-023-02140-w"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v30\/i9\/1253.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v30\/i9\/1253.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T09:24:52Z","timestamp":1709630692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v30\/i9\/1253.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":9,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.3748\/wjg.v30.i9.1253","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}